Neurohumoral and Hemodynamic Evaluation of Healthy Dogs Submitted to Doxorubicin Effects
World Small Animal Veterinary Association World Congress Proceedings, 2004
A.A. Camacho; R.C.A. Souza

This study aimed to evaluate some neurohumoral and hemodynamic alterations caused by chronic doxorubicin (DOXO) applications in the dog. These data could make easier the establishment of an early diagnosis of the toxicity caused by DOXO.

For such, 13 adult mongrel dogs, among males and females were used. Seven dogs received DOXO chloride (30mg/m2, IV, 8 injections given each 21 days) and six, were given 0,9% NaCl solution (5mL, IV, 8 injections given each 21 days). During the experimental period, it was performed both electrocardiographic and echocardiographic evaluation, besides blood pressure assessment, determination of heart rate variability and plasma renin activity (PRA), measurement of plasma norepinephrine and plasma brain natriuretic peptide.

Results showed that animals that received DOXO had significant decrease on R wave amplitude (starting at 60mg/m2), on both shortening and ejection fractions (after 90mg/m2), besides an increase in PRA (after 120mg/m2) and in left ventricle systolic and diastolic diameters (after 180mg/m2 and 210mg/m2, respectively).

These data allowed concluding that the treatment of dogs with DOXO can lead to cardiotoxicity after the dose of 60mg/m2 is reached. The echocardiography showed to be more sensible than the determination of PRA in the early detection of left ventricle dysfunction, which is secondary to the anthraciclinic toxicity. Moreover, dogs undergoing DOXO treatment can have different degrees of sensibility to the toxicity induced by this drug.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

A. A. Camacho
São Paulo State University (Unesp)
Campus of Jaboticabal, Brazil


MAIN : Abstracts : Doxorubicin Effects
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27